Entity Central Index Key
Process research and development.
Cover [Abstract]
Document Type
Document Type
Amendment Flag
Amendment Flag
Document Annual Report
Document Annual Report
Document Transition Report
Document Transition Report
Entity Interactive Data Current
Entity Interactive Data Current
Document Period End Date
Document Period End Date
Document Fiscal Year Focus
Document Fiscal Year Focus
Current Fiscal Year End Date
Current Fiscal Year End Date
Document Fiscal Period Focus
Document Fiscal Period Focus
Entity Registrant Name
Entity Registrant Name
Entity Central Index Key
Entity Tax Identification Number
Entity Tax Identification Number
Entity Current Reporting Status
Entity Current Reporting Status
Entity Voluntary Filers
Entity Voluntary Filers
Entity Well-known Seasoned Issuer
Entity Well Known Seasoned Issuer
Entity Filer Category
Entity Filer Category
Entity File Number
Entity File Number
Entity Shell Company
Entity Shell Company
Entity Emerging Growth Company
Entity Emerging Growth Company
Entity Ex Transition Period
Entity Ex Transition Period
Entity Small Business
Entity Small Business
ICFR Auditor Attestation Flag
Icfr Auditor Attestation Flag
Entity Incorporation, State or Country Code
Entity Incorporation State Country Code
Entity Address, Address Line One
Entity Address Address Line1
Entity Address, Address Line Two
Entity Address Address Line2
Entity Address, City or Town
Entity Address City Or Town
Entity Address, State or Province
Entity Address State Or Province
Entity Address, Postal Zip Code
Entity Address Postal Zip Code
City Area Code
City Area Code
Local Phone Number
Local Phone Number
Entity Common Stock, Shares Outstanding
Entity Common Stock Shares Outstanding
Entity Public Float
Entity Public Float
Title of 12(b) Security
Security12b Title
Trading Symbol
Trading Symbol
Security Exchange Name
Security Exchange Name
Accrued clinical trial expenses current.
Warrant liability current.
Statement Of Financial Position [Abstract]
Assets
Assets [Abstract]
Current assets:
Assets Current [Abstract]
Cash and cash equivalents
Cash And Cash Equivalents At Carrying Value
Prepaid expenses and other current assets (including related party amounts of $82 and $0, respectively)
Prepaid Expense And Other Assets Current
Total current assets
Assets Current
Property, plant and equipment, net
Property Plant And Equipment Net
Operating lease right-of-use assets
Operating Lease Right Of Use Asset
Other long-term assets
Other Assets Noncurrent
Total assets
Assets
Liabilities and Stockholders’ Equity
Liabilities And Stockholders Equity [Abstract]
Current liabilities:
Liabilities Current [Abstract]
Accounts payable (including related party amounts of $173 and $200, respectively)
Accounts Payable Current
Accrued clinical trial expenses
Accrued Clinical Trial Expenses Current
Accrued expenses (including related party amounts of $734 and $308, respectively)
Accrued Liabilities Current
Accrued interest
Interest Payable Current
Current portion of long-term debt
Long Term Debt Current
Operating lease liabilities, current
Operating Lease Liability Current
Warrant liabilities
Warrant Liability Current
Total current liabilities
Liabilities Current
Long-term debt, net of discount
Long Term Debt Noncurrent
Operating lease liabilities
Operating Lease Liability Noncurrent
Other long-term liabilities
Other Liabilities Noncurrent
Total liabilities
Liabilities
Commitments and contingencies (Note 4)
Commitments And Contingencies
Stockholders’ equity:
Stockholders Equity [Abstract]
Preferred stock, $0.0001 par value; authorized shares — 40,000,000 at December 31, 2020 and 2019; no shares issued and outstanding at December 31, 2020 and 2019
Preferred Stock Value
Common stock, $0.0001 par value; authorized shares —400,000,000 at December 31, 2020 and 2019; issued shares— 31,262,769 and 28,964,506 at December 31, 2020 and 2019, respectively; outstanding shares— 28,516,010 and 24,728,258 at December 31, 2020 and 2019, respectively
Common Stock Value
Additional paid-in capital
Additional Paid In Capital Common Stock
Accumulated deficit
Retained Earnings Accumulated Deficit
Total stockholders’ equity
Stockholders Equity
Total liabilities and stockholders’ equity
Liabilities And Stockholders Equity
Prepaid expenses and other assets related parties current.
Accrued expenses related parties current.
Prepaid expenses and other current assets, related parties
Prepaid Expenses And Other Assets Related Parties Current
Accounts payable, related parties
Accounts Payable Related Parties Current
Accrued expenses, related parties
Accrued Expenses Related Parties Current
Preferred stock, par value
Preferred Stock Par Or Stated Value Per Share
Preferred stock, authorized shares
Preferred Stock Shares Authorized
Preferred stock, issued shares
Preferred Stock Shares Issued
Preferred stock, outstanding shares
Preferred Stock Shares Outstanding
Common stock, par value
Common Stock Par Or Stated Value Per Share
Common stock, authorized shares
Common Stock Shares Authorized
Common stock, issued shares
Common Stock Shares Issued
Common stock, outstanding shares
Common Stock Shares Outstanding
Change in fair value of convertible promissory notes.
Income Statement [Abstract]
Operating expenses:
Operating Expenses [Abstract]
Research and development (includes related party amounts of $2,812 and $1,243, respectively)
Research And Development Expense
In-process research and development
Process Research And Development
General and administrative (includes related party amounts of $157 and $312, respectively)
General And Administrative Expense
Total operating expenses
Operating Expenses
Loss from operations
Operating Income Loss
Other income (expense):
Nonoperating Income Expense [Abstract]
Interest income
Investment Income Interest
Interest expense (includes related party amounts of $0 and $(590), respectively)
Interest Expense
Change in fair value of warrant liabilities (includes related party amounts of $0 and $(96,278), respectively)
Fair Value Adjustment Of Warrants
Change in fair value of convertible promissory notes (includes related party amounts of $0 and $(10,941), respectively)
Change In Fair Value Of Convertible Promissory Notes
Other income (expense)
Other Nonoperating Income Expense
Total other income (expense)
Nonoperating Income Expense
Net loss and comprehensive loss
Net Income Loss
Net loss per share, basic and diluted
Earnings Per Share Basic And Diluted
Weighted-average shares of common stock outstanding, basic and diluted
Weighted Average Number Of Share Outstanding Basic And Diluted
Research and development expense related party.
General and administrative expense related party.
Change in fair value of warrant liabilities related party.
Change in fair value of convertible promissory notes related party.
Research and development expenses, related party
Research And Development Expense Related Party
General and administrative expenses, related party
General And Administrative Expense Related Party
Interest expense, related party
Interest Expense Related Party
Change in fair value of warrant liabilities, related party
Change In Fair Value Of Warrant Liabilities Related Party
Change in fair value of convertible promissory notes, related party
Change In Fair Value Of Convertible Promissory Notes Related Party
Vesting restrictions placed on previously issued and outstanding shares of common stock.
Vesting restrictions placed on previously issued and outstanding value of common stock.
Adjustments to additional paid in capital conversion of warrant liability into equity.
Statement Of Stockholders Equity [Abstract]
Statement [Table]
Statement [Table]
Equity Components
Statement Equity Components [Axis]
Equity Component
Equity Component [Domain]
Common Stock
Common Stock [Member]
Additional Paid-in Capital
Additional Paid In Capital [Member]
Accumulated Deficit
Retained Earnings [Member]
Sale of Stock
Subsidiary Sale Of Stock [Axis]
Sale of Stock
Sale Of Stock Name Of Transaction [Domain]
Underwritten Public Offering
Over Allotment Option [Member]
IPO
I P O [Member]
Collaborative Arrangement and Arrangement Other than Collaborative
Type Of Arrangement [Axis]
Collaborative Arrangement and Arrangement Other than Collaborative
Arrangements And Nonarrangement Transactions [Member]
Takeda license agreement.
Takeda License
Takeda License Agreement [Member]
Related Party
Related Party Transactions By Related Party [Axis]
Related Party
Related Party [Domain]
Frazier
Principal Owner [Member]
Statement [Line Items]
Statement [Line Items]
Beginning balance
Beginning balance, shares
Merger of entities under common control into the Company
Stock Issued During Period Value Acquisitions
Merger of entities under common control into the Company, shares
Stock Issued During Period Shares Acquisitions
Vesting restrictions placed on previously issued and outstanding common stock
Vesting Restrictions Placed On Previously Issued And Outstanding Value Of Common Stock
Vesting restrictions placed on previously issued and outstanding common stock, shares
Vesting Restrictions Placed On Previously Issued And Outstanding Shares Of Common Stock
Issuance of common stock
Stock Issued During Period Value New Issues
Issuance of common stock, shares
Stock Issued During Period Shares New Issues
Conversion of warrant liability into equity
Adjustments To Additional Paid In Capital Conversion Of Warrant Liability Into Equity
Conversion of May 2019 Notes and accrued interest into common shares
Stock Issued During Period Value Conversion Of Convertible Securities
Conversion of May 2019 Notes and accrued interest into common shares, shares
Stock Issued During Period Shares Conversion Of Convertible Securities
Issuance of common stock from exercise of stock options
Stock Issued During Period Value Stock Options Exercised
Issuance of common stock from exercise of stock options, shares
Stock Issued During Period Shares Stock Options Exercised
Vesting of restricted shares
Stock Issued During Period Value Restricted Stock Award Gross
Vesting of restricted shares, shares
Stock Issued During Period Shares Restricted Stock Award Gross
Stock-based compensation
Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
Net loss
Ending balance
Ending balance, shares
Fair value adjustment of convertible promissory notes.
Increase decrease in clinical accrued trial expenses.
Increase (decrease) in operating right of use asset and lease liabilities.
Proceeds from underwritten public offering, net.
Non cash issuance of warrants.
Issuance of common stock warrants in connection with long-term debt.
Non cash final interest payment fee.
Operating lease liabilities arising from obtaining right-of-use assets
Conversion of warrant liabilities into equity.
Unpaid underwritten public offering costs.
Statement Of Cash Flows [Abstract]
Class of Warrant or Right
Class Of Warrant Or Right [Axis]
Class of Warrant or Right
Class Of Warrant Or Right [Domain]
Takeda warrants.
Takeda Warrants
Takeda Warrants [Member]
Lender warrants.
Lender Warrants
Lender Warrants [Member]
Cash flows from operating activities
Net Cash Provided By Used In Operating Activities [Abstract]
Net loss
Profit Loss
Adjustments to reconcile net loss to net cash used in operating activities:
Adjustments To Reconcile Net Income Loss To Cash Provided By Used In Operating Activities [Abstract]
Depreciation and amortization
Depreciation Depletion And Amortization
Stock-based compensation
Share Based Compensation
Amortization of debt discount
Amortization Of Financing Costs
Acquired in-process research and development
Research And Development In Process
Non-cash interest expense (includes related party amounts of $0 and $590, respectively)
Interest Expense Other
Change in fair value of warrant liabilities (includes related party amounts of $0 and $96,278, respectively)
Change in fair value of convertible promissory notes (includes related party amounts of $0 and $10,941, respectively)
Fair Value Adjustment Of Convertible Promissory Notes
Other
Other Expenses
Changes in operating assets and liabilities:
Increase Decrease In Operating Capital [Abstract]
Prepaid expenses and other current assets (includes related party amounts of $(82) and $19, respectively)
Increase Decrease In Prepaid Deferred Expense And Other Assets
Accounts payable and accrued expenses (includes related party amounts of $399 and $460, respectively)
Increase Decrease In Accounts Payable And Accrued Liabilities
Accrued clinical trial expenses
Increase Decrease In Clinical Accrued Trial Expenses
Accrued interest
Increase Decrease In Interest Payable Net
Operating right-of-use asset and lease liabilities
Increase Decrease In Operating Right Of Use Asset And Lease Liabilities
Other long-term assets
Increase Decrease In Other Noncurrent Assets
Net cash used in operating activities
Net Cash Provided By Used In Operating Activities
Cash flows from investing activities
Net Cash Provided By Used In Investing Activities [Abstract]
Cash paid for purchased in-process research and development
Payments To Acquire In Process Research And Development
Cash paid for property, plant and equipment
Payments To Acquire Property Plant And Equipment
Net cash used in investing activities
Net Cash Provided By Used In Investing Activities
Cash flows from financing activities
Net Cash Provided By Used In Financing Activities [Abstract]
Proceeds from initial public offering, net of issuance costs
Proceeds From Issuance Initial Public Offering
Proceeds from underwritten public offering, net
Proceeds From Underwritten Public Offering Net
Proceeds from issuance of common stock from exercise of stock options
Proceeds From Stock Options Exercised
Proceeds from issuance of convertible promissory notes
Proceeds From Issuance Of Convertible Preferred Stock
Net proceeds from issuance of long-term debt
Proceeds From Issuance Of Long Term Debt
Net cash provided by financing activities
Net Cash Provided By Used In Financing Activities
Net increase in cash and cash equivalents
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
Cash and cash equivalents – beginning of period
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
Cash and cash equivalents – end of period
Supplemental disclosure of cash flow information
Supplemental Cash Flow Information [Abstract]
Interest paid
Interest Paid Net
Supplemental disclosure of noncash investing and financing activities
Cash Flow Noncash Investing And Financing Activities Disclosure [Abstract]
Exchange of accrued interest for convertible promissory notes
Conversion Of Stock Amount Converted1
Issuance of Takeda Warrants in connection with Takeda License
Non Cash Issuance Of Warrants
Issuance of common stock in connection with Takeda License
Stock Issued1
Issuance of common stock warrants in connection with long-term debt
Issuance Of Common Stock Warrants In Connection With Long Term Debt
Property and equipment purchases included in accounts payable and accrued expenses
Capital Expenditures Incurred But Not Yet Paid
Final interest payment fee
Non Cash Final Interest Payment Fee
Operating lease liabilities arising from obtaining right-of-use assets
Operating Lease Liabilities Arising From Obtaining Right Of Use Assets
Conversion of Lender Warrants into Equity
Conversion Of Warrant Liabilities Into Equity
Conversion of convertible promissory notes and accrued interest into common shares
Debt Conversion Converted Instrument Amount1
Underwritten public offering costs included in accounts payable and accrued expenses
Unpaid Underwritten Public Offering Costs
Increase (decrease)in prepaid expenses and other assets related parties current.
Increase (decrease) in accounts payable and accrued expenses related parties.
Non cash interest expense related party.
Non-cash interest expense, related party
Non Cash Interest Expense Related Party
Change in fair value of warrant liabilities related party
Change in fair value of convertible promissory notes related party
Related parties prepaid expenses and other assets current
Increase Decrease In Prepaid Expenses And Other Assets Related Parties Current
Related parties accounts payable and accrued expenses
Increase Decrease In Accounts Payable And Accrued Expenses Related Parties
Documents Incorporated by Reference
Documents Incorporated By Reference [Text Block]
Organization Consolidation And Presentation Of Financial Statements [Abstract]
Organization, Basis of Presentation and Summary of Significant Accounting Policies
Organization Consolidation And Presentation Of Financial Statements Disclosure And Significant Accounting Policies [Text Block]
Component of Balance Sheet Disclosure.
Balance Sheet Related Disclosures [Abstract]
Balance Sheet Details
Component Of Balance Sheet Disclosure [Text Block]
Related Party Transactions [Abstract]
Related Party Transactions
Related Party Transactions Disclosure [Text Block]
Commitments And Contingencies Disclosure [Abstract]
Commitments and Contingencies
Commitments And Contingencies Disclosure [Text Block]
Convertible promissory notes.
Debt Disclosure [Abstract]
Convertible Promissory Notes
Convertible Promissory Notes [Text Block]
Leases [Abstract]
Lease Commitments
Lessee Operating Leases [Text Block]
Debt
Debt Disclosure [Text Block]
Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]
Stockholders' Equity
Disclosure Of Compensation Related Costs Share Based Payments [Text Block]
Income Tax Disclosure [Abstract]
Income Taxes
Income Tax Disclosure [Text Block]
Compensation And Retirement Disclosure [Abstract]
401(k) Plan
Defined Contribution Plan [Text Block]
Quarterly Financial Information Disclosure [Abstract]
Quarterly Financial Information (unaudited)
Quarterly Financial Information [Text Block]
Subsequent Events [Abstract]
Subsequent Events
Subsequent Events [Text Block]
Basis of Presentation
Basis Of Accounting Policy Policy [Text Block]
Liquidity and capital resources.
Liquidity and Capital Resources
Liquidity And Capital Resources Policy [Text Block]
Use of Estimates
Use Of Estimates
Fair value option.
Fair Value Option
Fair Value Option Policy [Text Block]
Fair Value Measurements
Fair Value Measurement Policy Policy [Text Block]
Cash and Cash Equivalents
Cash And Cash Equivalents Policy [Text Block]
Concentrations of Credit Risk
Concentration Risk Credit Risk
Property, Plant, and Equipment, Net
Property Plant And Equipment Policy [Text Block]
Impairment of Long-Lived Assets
Impairment Or Disposal Of Long Lived Assets Policy [Text Block]
Leases
Lessor Leases Policy [Text Block]
Research and Development Expenses and Accruals
Research And Development Expense Policy
In-Process Research and Development
In Process Research And Development Policy
General and Administrative Expenses
Selling General And Administrative Expenses Policy [Text Block]
Stock-Based Compensation
Compensation Related Costs Policy [Text Block]
Income Taxes
Income Tax Policy [Text Block]
Comprehensive Loss
Comprehensive Income Policy Policy [Text Block]
Segment Reporting
Segment Reporting Policy Policy [Text Block]
Net Loss Per Share
Earnings Per Share Policy [Text Block]
Recently Adopted and Issued Accounting Pronouncements
New Accounting Pronouncements Policy Policy [Text Block]
Schedule of Reconciliation of Liabilities Measured at Fair Value
Fair Value Liabilities Measured On Recurring Basis Unobservable Input Reconciliation [Text Block]
Schedule of Property, Plant and Equipment, Net
Property Plant And Equipment [Text Block]
Schedule of Accrued Expenses
Schedule Of Accrued Liabilities Table [Text Block]
Summary of supplemental balance sheet information related to operating leases.
Summary of Supplemental Balance Sheet Information Related to the Operating Leases
Summary Of Supplemental Balance Sheet Information Related To Operating Leases Table [Text Block]
Summary of Future Minimum Lease Payments Under Operating Leases
Lessee Operating Lease Liability Maturity Table [Text Block]
Schedule of Total Debt
Schedule Of Debt Instruments [Text Block]
Schedule of Future Minimum Principal and Interest Payments Under Term Loans
Schedule Of Maturities Of Long Term Debt Table [Text Block]
Plan Name
Plan Name [Axis]
Plan Name
Plan Name [Domain]
Employee stock purchase plan.
Employee Stock Purchase Plan
Employee Stock Purchase Plan [Member]
Summary of Unvested Shares
Schedule Of Unvested Restricted Stock Units Roll Forward Table [Text Block]
Common stock reserved for future issuances.
Summary of Common Stock Reserved for Future Issuance
Common Stock Reserved For Future Issuances Table Table [Text Block]
Summary of PSU Activity Under the 2019 Incentive Award Plan
Schedule Of Nonvested Performance Based Units Activity Table [Text Block]
Summary of Weighted-Average Assumptions Used to Estimate Fair Value of Stock Options Granted and ESPP Awards
Schedule Of Share Based Payment Award Stock Options Valuation Assumptions Table [Text Block]
Summary of Stock Option Activity
Schedule Of Share Based Compensation Stock Options Activity Table [Text Block]
Summary of Stock-Based Compensation Expense
Schedule Of Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Text Block]
Reconciliation Between Provision for Income Taxes and Income Taxes Computed Using U.S. Federal Statutory Corporate Tax Rate
Schedule Of Effective Income Tax Rate Reconciliation Table [Text Block]
Components of Deferred Tax Assets
Schedule Of Deferred Tax Assets And Liabilities Table [Text Block]
Summary of Activity Related to Gross Unrecognized Benefits
Summary Of Income Tax Contingencies [Text Block]
Schedule of Quarterly Financial Information (unaudited)
Schedule Of Quarterly Financial Information Table [Text Block]
Organization basis of presentation and summary of significant accounting policies.
Organization basis of presentation and summary of significant accounting policies.
Organization Basis Of Presentation And Summary Of Significant Accounting Policies [Table]
Organization Basis Of Presentation And Summary Of Significant Accounting Policies [Table]
Measurement Frequency
Fair Value By Measurement Frequency [Axis]
Measurement Frequency
Fair Value Measurement Frequency [Domain]
Fair Value, Recurring
Fair Value Measurements Recurring [Member]
Fair Value, Nonrecurring
Fair Value Measurements Nonrecurring [Member]
Statistical Measurement
Range [Axis]
Statistical Measurement
Range [Member]
Minimum
Minimum [Member]
Maximum
Maximum [Member]
Long-Lived Tangible Asset
Property Plant And Equipment By Type [Axis]
Long-Lived Tangible Asset
Property Plant And Equipment Type [Domain]
Computer equipment and software.
Computer Equipment and Related Software
Computer Equipment And Software [Member]
Furniture and Fixtures
Furniture And Fixtures [Member]
Antidilutive Securities
Antidilutive Securities Excluded From Computation Of Earnings Per Share By Antidilutive Securities [Axis]
Antidilutive Securities, Name
Antidilutive Securities Name [Domain]
Unvested shares.
Unvested Shares
Unvested Shares [Member]
Takeda Warrant
Takeda pharmaceutical company limited.
Takeda
Takeda Pharmaceutical Company Limited [Member]
Accounting Standards Update
Adjustments For New Accounting Pronouncements [Axis]
Accounting Standards Update
Type Of Adoption [Member]
Accounting Standards Update 2016-13
Accounting Standards Update201613 [Member]
Accounting Standards Update 2018-13
Accounting Standards Update201813 [Member]
Organization Basis Of Presentation And Summary Of Significant Accounting Policies [Line Items]
Organization Basis Of Presentation And Summary Of Significant Accounting Policies [Line Items]
Common stock shares issued
Proceeds from Initial Public Offering (IPO)
Public offering price per share
Shares Issued Price Per Share
Offering costs
Deferred Offering Costs
Financial assets fair value disclosure.
Nonfinancial assets fair value disclosure.
Financial assets fair value disclosure
Financial Assets Fair Value Disclosure
Non-financial assets fair value disclosure
Nonfinancial Assets Fair Value Disclosure
Non-financial liabilities fair value disclosure
Nonfinancial Liabilities Fair Value Disclosure
Fair value liabilities, level 1 to level 2 transfers, amount
Fair Value Liabilities Level1 To Level2 Transfers Amount
Fair value liabilities, level 2 to level 1 transfers, amount
Fair Value Liabilities Level2 To Level1 Transfers Amount
Fair value liability, transfers into level 3
Fair Value Measurement With Unobservable Inputs Reconciliation Liability Transfers Into Level3
Fair value liability, transfers out of level 3
Fair Value Measurement With Unobservable Inputs Reconciliation Liability Transfers Out Of Level3
Expected cash dividend yield rate.
Expected cash dividend yield
Expected Cash Dividend Yield Rate
Conversion of Lender Warrants into equity
Fair value measurement with unobservable inputs reconciliations recurring basis liability issuance of convertible promissory notes.
Fair value measurement with unobservable inputs reconciliations recurring basis liability exchange of convertible promissory notes.
Fair value measurement with unobservable inputs reconciliations recurring basis liability issuance of warrants.
Fair value measurement with unobservable inputs reconciliations recurring basis conversion of convertible promissory notes into common shares upon initial public offering.
Fair value measurement with unobservable inputs reconciliations recurring basis reclass of warrant into equity.
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Table]
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Table]
Debt Instrument
Debt Instrument [Axis]
Debt Instrument, Name
Debt Instrument Name [Domain]
Convertible promissory notes due in may two thousand and nineteen.
Convertible Promissory Notes
Convertible Promissory Notes Due In May Two Thousand And Nineteen [Member]
Warrants liabilities.
Warrant Liabilities
Warrants Liabilities [Member]
Fair Value Hierarchy and NAV
Fair Value By Fair Value Hierarchy Level [Axis]
Fair Value Hierarchy and NAV
Fair Value Measurements Fair Value Hierarchy [Domain]
Significant Unobservable Inputs (Level 3)
Fair Value Inputs Level3 [Member]
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Beginning Balance
Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Liability Value
Issuance of convertible promissory notes
Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Liability Issuance Of Convertible Promissory Notes
Exchange of convertible promissory notes (Note 4)
Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Liability Exchange Of Convertible Promissory Notes
Issuance of warrants
Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Liability Issuance Of Warrants
Change in fair value
Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Period Increase Decrease
Conversion of May 2019 Notes into common shares upon IPO (Note 5)
Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Conversion Of Convertible Promissory Notes Into Common Shares Upon Initial Public Offering
Ending Balance
Reclassification of Warrants into Equity
Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Reclass Of Warrants Into Equity
Property and equipment, useful life
Property Plant And Equipment Useful Life
Impairment losses
Impairment Of Long Lived Assets To Be Disposed Of
Number of operating segment
Number Of Operating Segments
Incremental common shares attributable to exercise of warrants.
Shares of common stock included in calculation of basic weighted-average common shares
Incremental Common Shares Attributable To Exercise Of Warrants
Weighted-average unvested shares
Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
Change in accounting principle, Accounting Standards Update, adopted [true false]
Change In Accounting Principle Accounting Standards Update Adopted
Change in accounting principle, Accounting Standards Update, Adoption date
Change In Accounting Principle Accounting Standards Update Adoption Date
Change in accounting principle, Accounting Standards Update, Immaterial effect [true false]
Change In Accounting Principle Accounting Standards Update Immaterial Effect
Property Plant And Equipment [Abstract]
Schedule Of Property Plant And Equipment [Table]
Schedule Of Property Plant And Equipment [Table]
Computer Equipment
Computer Equipment [Member]
Leasehold Improvements
Leasehold Improvements [Member]
Property Plant And Equipment [Line Items]
Property Plant And Equipment [Line Items]
Property, plant and equipment, gross
Property Plant And Equipment Gross
Less: accumulated depreciation
Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
Total property, plant and equipment, net
Depreciation expense
Depreciation
Disposal of property, plant or equipment
Property Plant And Equipment Disposals
Accrued research and development expenses.
Accrued Liabilities Current [Abstract]
Accrued research and development expenses
Accrued Research And Development Expenses
Accrued compensation expenses
Accrued Employee Benefits Current
Accrued professional & consulting expenses
Accrued Professional Fees Current
Accrued other
Other Accrued Liabilities Current
Total accrued expenses
Accounts payable and accrued expenses related parties current.
Related party transaction shared operating expenses due to transactions with related party.
Schedule Of Related Party Transactions By Related Party [Table]
Schedule Of Related Party Transactions By Related Party [Table]
PCI Pharma Services.
PCI Pharma Services
P C I Pharma Services [Member]
Related Party Transaction
Related Party Transaction [Axis]
Related Party Transaction
Related Party Transaction [Domain]
Clinical manufacturing services.
Clinical Manufacturing Services
Clinical Manufacturing Services [Member]
Mountain field LLC.
Mountain Field LLC
Mountain Field Limited Liability Corporation [Member]
Takeda License Agreement
Drug product.
Drug Product
Drug Product [Member]
Commercial supply agreement.
Commercial Supply Agreement
Commercial Supply Agreement [Member]
Temporary services agreement.
Temporary Services Agreement
Temporary Services Agreement [Member]
Related Party Transaction [Line Items]
Related Party Transaction [Line Items]
Outstanding accounts payable and accrued expenses
Accounts Payable And Accrued Expenses Related Parties Current
Shared operating expenses
Related Party Transaction Shared Operating Expenses Due To Transactions With Related Party
Expense related to services
Related Party Transaction Expenses From Transactions With Related Party
Related party transaction shared operating expenses due from transactions with related party.
Shared operating expenses
Related Party Transaction Shared Operating Expenses Due From Transactions With Related Party
Agreement extends period for termination.
Agreement extends period for termination
Agreement Extends Period For Termination
Minimum purchase obligation
Purchase Obligation
Agreement expiration term from date of first commercial sale.
License agreement description.
Commitments and contingencies.
Commitments and contingencies.
Commitments And Contingencies [Table]
Commitments And Contingencies [Table]
Commitments And Contingencies [Line Items]
Commitments And Contingencies [Line Items]
License agreement description
License Agreement Description
Agreement expiration term from date of first commercial sale
Agreement Expiration Term From Date Of First Commercial Sale
Payment for license amount.
Additional warrant issued.
Maximum amount payable in sales milestones upon the achievement of specified levels of product sales.
License agreement transaction costs.
Warrants expiration date.
Cash consideration paid for license
Payment For License Amount
Common stock fair value
Common stock, shares issued
Warrants issued to purchase shares
Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights
Warrants exercise price
Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1
Initial fair value of warrants
Warrants And Rights Outstanding
Additional warrant issued
Additional Warrant Issued
Maximum amount payable in sales milestones upon achievement of specified levels of product sales
Maximum Amount Payable In Sales Milestones Upon Achievement Of Specified Levels Of Product Sales
Transaction costs
License Agreement Transaction Costs
Warrants expiration date
Warrants Expiration Date
Common stock, shares authorized
Fair value adjustment of warrants
Purchase obligation due in first twenty four months.
Purchase commitment, expense.
Purchase obligation in the first 24-month period
Purchase Obligation Due In First Twenty Four Months
Expenses incurred related to purchase commitments
Purchase Commitment Expense
Debt Instrument [Table]
Debt Instrument [Table]
Frazier convertible note financing member.
Frazier Convertible Note Financing
Frazier Convertible Note Financing [Member]
May two thousand and nineteen convertible note financing member.
May 2019 Convertible Note Financing
May Two Thousand And Nineteen Convertible Note Financing [Member]
Income Statement Location
Income Statement Location [Axis]
Income Statement Location
Income Statement Location [Domain]
Other Income (Expense)
Other Nonoperating Income Expense [Member]
Partner Type
Partner Type Of Partners Capital Account [Axis]
Partner Type of Partners' Capital Account, Name
Partner Type Of Partners Capital Account Name [Domain]
Frazier Life Sciences IX, limited partner member.
Frazier
Frazier Life Sciences I X Limited Partner [Member]
Debt Instrument [Line Items]
Debt Instrument [Line Items]
Aggregate amount of debt instrument
Debt Instrument Face Amount
Debt instrument, interest rate percentage
Debt Instrument Interest Rate Effective Percentage
Debt instrument issued, amount
Proceeds From Convertible Debt
Fair value of convertible promissory notes
Convertible Debt Fair Value Disclosures
Increases (decreases) in fair value of debt instrument
Debt Instrument Increase Decrease For Period Net
Interest expense
Interest Expense Debt
Proceeds from issuance of unsecured debt
Proceeds From Issuance Of Unsecured Debt
Debt instrument purchased amount
Debt Instrument Repurchase Amount
Debt instrument conversion, shares issued
Debt Conversion Converted Instrument Shares Issued1
Lessee operating lease number of option to extend.
Lessee Lease Description [Table]
Lessee Lease Description [Table]
Geographical
Statement Geographical [Axis]
Geographical
Segment Geographical [Domain]
Buffalo Grove, Illinois
ISRAEL
Florham Park, New Jersey
JERSEY
Balance Sheet Location
Balance Sheet Location [Axis]
Balance Sheet Location
Balance Sheet Location [Domain]
Prepaid lease payments.
Prepaid Lease Payments
Prepaid Lease Payments [Member]
Lessee Lease Description [Line Items]
Lessee Lease Description [Line Items]
Operating leases, remaining lease terms
Lessee Operating Lease Remaining Lease Term
Operating lease number of option to extend
Lessee Operating Lease Number Of Option To Extend
Operating lease, option to extend description
Lessee Operating Lease Option To Extend
Lessee, operating lease, existence of option to terminate
Lessee Operating Lease Existence Of Option To Terminate
Operating lease, renewal term
Lessee Operating Lease Renewal Term
Operating leases, rent expense
Operating Lease Expense
Assets, lessee.
Liabilities, lessee.
Assets:
Assets Lessee [Abstract]
Liabilities:
Liabilities Lessee [Abstract]
Operating lease liabilities, non-current
Total operating lease liabilities
Operating Lease Liability
2021
Lessee Operating Lease Liability Payments Due Next Twelve Months
2022
Lessee Operating Lease Liability Payments Due Year Two
2023
Lessee Operating Lease Liability Payments Due Year Three
2024
Lessee Operating Lease Liability Payments Due Year Four
2025
Lessee Operating Lease Liability Payments Due Year Five
Total minimum lease payments
Lessee Operating Lease Liability Payments Due
Less: amount representing interest
Lessee Operating Lease Liability Undiscounted Excess Amount
Less: operating lease liabilities, current
Weighted-average remaining lease term (in years)
Operating Lease Weighted Average Remaining Lease Term1
Weighted-average incremental borrowing rate
Operating Lease Weighted Average Discount Rate Percent
Cash payments for operating lease costs
Operating Lease Payments
Long term debt noncurrent excluding unamortized debt discount.
Long-term debt, current portion
Long-term debt, non-current portion
Long Term Debt Noncurrent Excluding Unamortized Debt Discount
Unamortized debt discount
Debt Instrument Unamortized Discount
Total debt, net of debt discount
Long Term Debt
Debt instrument additional borrowing capacity amount.
Long-term Debt, Type
Longterm Debt Type [Axis]
Long-term Debt, Type
Longterm Debt Type [Domain]
Term loan.
Term Loans
Term Loan [Member]
Variable Rate
Variable Rate [Axis]
Variable Rate
Variable Rate [Domain]
Prime Rate
Prime Rate [Member]
Loan agreement.
Loan Agreement
Loan Agreement [Member]
Debt instrument, additional borrowing capacity amount
Debt Instrument Additional Borrowing Capacity Amount
Debt instrument final payment fee percentage.
Debt instrument final payment fee.
Debt instrument, basis spread on variable rate
Debt Instrument Basis Spread On Variable Rate1
Debt instrument, description
Debt Instrument Payment Terms
Debt instrument, maturity date
Debt Instrument Maturity Date
Debt instrument, final payment fee percentage
Debt Instrument Final Payment Fee Percentage
Debt instrument, final payment fee
Debt Instrument Final Payment Fee
Debt instrument prepayment fee percentage of outstanding principal amount.
Debt instrument, prepayment fee percentage of outstanding principal amount
Debt Instrument Prepayment Fee Percentage Of Outstanding Principal Amount
Interest bearing rate upon customary events.
Interest bearing rate upon customary events
Interest Bearing Rate Upon Customary Events
Lender warrants exercisable shares of common stock.
Lander warrants expire term.
Warrants exercisable shares of common stock
Lender Warrants Exercisable Shares Of Common Stock
Warrants expire term
Lander Warrants Expire Term
Aggregate repurchase price of warrants
Payments For Repurchase Of Warrants
Adjustments to additional paid-in-capital, warrants issued
Adjustments To Additional Paid In Capital Warrant Issued
Accrued interest.
Fair value of warrant liabilities
Debt issuance costs
Unamortized Debt Issuance Expense
Long-term debt outstanding
Debt Instrument Carrying Amount
Accrued interest
Accrued Interest
Long term debt maturities repayments of principal and interest, year one.
Long term debt maturities repayments of principal and interest in year two.
Long term debt maturities repayments of principal and interest in year three.
Long term debt maturities repayments of principal and interest in year four.
Long term debt and interest.
Debt instrument interest and final payment fee.
2021
Long Term Debt Maturities Repayments Of Principal And Interest Due Next Twelve Months
2022
Long Term Debt Maturities Repayments Of Principal And Interest In Year Two
2023
Long Term Debt Maturities Repayments Of Principal And Interest In Year Three
2024
Long Term Debt Maturities Repayments Of Principal And Interest In Year Four
Total principal and interest payments
Long Term Debt And Interest
Less interest and final payment fee
Debt Instrument Interest And Final Payment Fee
Total term loan borrowings
Schedule Of Share Based Compensation Arrangements By Share Based Payment Award [Table]
Schedule Of Share Based Compensation Arrangements By Share Based Payment Award [Table]
Title of Individual
Title Of Individual [Axis]
Title of Individual
Title Of Individual With Relationship To Entity [Domain]
Founders.
Founders
Founders [Member]
Vesting
Vesting [Axis]
Vesting
Vesting [Domain]
First Anniversary
Share Based Compensation Award Tranche One [Member]
Grantee Status
Grantee Status [Axis]
Grantee Status
Grantee Status [Domain]
Employees.
Employees
Employees [Member]
Open Market Sale Agreement with Jefferies LLC.
Open Market Sale Agreement with Jefferies LLC
Open Market Sale Agreement With Jefferies L L C [Member]
At-the-market offering program.
At-the-Market Offering Program
A T M Offering Program [Member]
2019 equity incentive plan.
2019 Equity Incentive Plan
Two Thousand Nineteen Equity Incentive Plan [Member]
Award Type
Award Type [Axis]
Award Type
Share Based Compensation Arrangements By Share Based Payment Award Award Type And Plan Name [Domain]
Restricted Stock
Restricted Stock [Member]
Two thousand nineteen incentive award plan.
2019 Incentive Award Plan
Two Thousand Nineteen Incentive Award Plan [Member]
Performance-Based Stock Units (PSU)
Performance Shares [Member]
Subsequent Event Type
Subsequent Event Type [Axis]
Subsequent Event Type
Subsequent Event Type [Domain]
Subsequent Event
Subsequent Event [Member]
Stock Options
Employee Stock Option [Member]
Share-based payment arrangement, employee and nonemployee.
Employee and Nonemployee Director
Share Based Payment Arrangement Employee And Nonemployee [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Shares issued
Stock repurchase program, number of shares right lapse.
Number of shares authorized to repurchase
Stock Repurchase Program Number Of Shares Authorized To Be Repurchased
Stock repurchase program, number of shares right lapse
Stock Repurchase Program Number Of Shares Right Lapse
Remaining number of shares to be repurchased
Stock Repurchase Program Remaining Number Of Shares Authorized To Be Repurchased
Stock repurchase program, period in force
Stock Repurchase Program Period In Force1
Stock repurchase program expiration date
Stock Repurchase Program Expiration Date
Repurchase right lapse rate.
Repurchase right lapse shares.
Shares aggregate repurchase price.
Proceeds from issuance of shares
Proceeds From Issuance Of Common Stock
Repurchase right lapse rate
Repurchase Right Lapse Rate
Repurchase right lapse each month after first anniversary, shares
Repurchase Right Lapse Shares
Repurchases of shares
Stock Repurchased During Period Shares
Shares aggregate repurchase price
Shares Aggregate Repurchase Price
Common stock, price per share
Sale Of Stock Price Per Share
Percentage of gross sales price per share sold.
Percentage of gross sales price per share sold
Percentage Of Gross Sales Price Per Share Sold
Proceeds from issuance initial public offering gross.
Shares issued, price per share after deductions.
Net proceeds after deducting underwriters commission.
Purchase of additional offering expenses.
Option to purchase additional shares.
Period to purchase additional shares.
Additional shares purchased during option expiration.
Proceeds from issuance initial public offering gross
Proceeds From Issuance Initial Public Offering Gross
Purchase price per share after deducting underwriting discounts and commissions
Shares Issued Price Per Share After Deductions
Net proceeds after deducting underwriters commission
Net Proceeds After Deducting Underwriters Commission
Purchase of additional offering expenses
Purchase Of Additional Offering Expenses
Option to purchase additional shares
Option To Purchase Additional Shares
Option to purchase additional shares period
Period To Purchase Additional Shares
Additional shares purchased, 30-day option expiration
Additional Shares Purchased During Option Expiration
Share-based compensation arrangement by share-based payment award, equity instruments other than options, share vesting.
Balance at December 31, 2019
Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Number
Share vesting
Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Share Vesting
Balance at December 31, 2020
Schedule Of Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Table]
Schedule Of Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Table]
ESPP Plan
Stock options and performance-based awards.
Stock Options and Performance-Based Awards Outstanding
Stock Options And Performance Based Awards [Member]
Common stock warrants.
Common stock warrants
Common Stock Warrant [Member]
Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]
Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]
Common stock reserved for future issuance (in shares)
Common Stock Capital Shares Reserved For Future Issuance
Preferred stock, shares authorized
Preferred stock, shares issued
Preferred stock, shares outstanding
Common stock, shares authorized for issuance
Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Authorized
Number of shares available for issuance
Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant
Stock options, granted
Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
Stock awards, granted
Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period
Share based compensation arrangement by share based payment award number of shares available for grant annual increase.
Additional number of shares available for issuance
Share Based Compensation Arrangement By Share Based Payment Award Number Of Additional Shares Authorized
Annual increase to shares available for issuance percentage of outstanding common stock
Share Based Compensation Arrangement By Share Based Payment Award Percentage Of Outstanding Stock Maximum
Equity plan, description
Share Based Compensation Arrangement By Share Based Payment Award Description
Number of shares remain available for issuance, annual increase
Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant Annual Increase
Stock-based compensation cost
Allocated Share Based Compensation Expense
Number of Stock Units, Granted
Number of Stock Units, Vested
Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested In Period
Number of Stock Units, Forfeited
Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Forfeited In Period
Weighted Average Grant Date Fair Value Per Share, Unvested Beginning Balance
Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Weighted Average Grant Date Fair Value
Weighted Average Grant Date Fair Value Per Share, Granted
Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period Weighted Average Grant Date Fair Value
Weighted Average Grant Date Fair Value Per Share, Vested
Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested In Period Weighted Average Grant Date Fair Value
Weighted Average Grant Date Fair Value Per Share, Forfeited
Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Forfeitures Weighted Average Grant Date Fair Value
Weighted Average Grant Date Fair Value Per Share, Unvested Ending Balance
Unrecognized stock-based compensation expense
Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized
Common stock initially reserved for issuance
Maximum percentage of eligible compensation contributed by participants
Share Based Compensation Arrangement By Share Based Payment Award Maximum Employee Subscription Rate
Assumptions:
Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions And Methodology [Abstract]
Expected term (in years)
Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
Expected volatility
Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
Risk free interest rate
Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
Dividend yield
Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
Estimated weighted-average fair value
Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
Unrecognized stock-based compensation expense
Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options
Unrecognized stock-based compensation expense, weighted-average period for recognition
Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1
Share based compensation arrangement by share based payment award stock options exercised and shares vested.
Options Outstanding, Beginning Balance
Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
Options Outstanding, Options granted
Options Outstanding, Options exercised and shares vested
Share Based Compensation Arrangement By Share Based Payment Award Stock Options Exercised And Shares Vested
Options Outstanding, Options cancelled
Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
Options Outstanding, Ending Balance
Options Outstanding, Options exercisable as of December 31, 2020
Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
Options Outstanding, Options vested and expected to vest as of December 31, 2020
Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number
Share based compensation arrangements by share based payment award options exercises and shares vested in period weighted average exercise price.
Weighted-Average Exercise Price, Beginning Balance
Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
Weighted-Average Exercise Price, Options granted
Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
Weighted-Average Exercise Price, Options exercised and shares vested
Share Based Compensation Arrangements By Share Based Payment Award Options Exercises And Shares Vested In Period Weighted Average Exercise Price
Weighted-Average Exercise Price, Options cancelled
Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price
Weighted-Average Exercise Price, Ending Balance
Weighted-Average Exercise Price, Options exercisable as of December 31, 2020
Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
Weighted-Average Exercise Price, Options vested and expected to vest as of December 31, 2020
Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price
Weighted-Average Remaining Contractual Term
Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
Weighted-Average Remaining Contractual Term, Options exercisable
Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1
Weighted-Average Remaining Contractual Term, Options vested and expected to vest
Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term1
Aggregate Intrinsic Value, Balance
Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
Aggregate Intrinsic Value, Options exercisable
Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1
Aggregate Intrinsic Value, Options vested and expected to vest
Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Aggregate Intrinsic Value
Closing market price of common stock.
Closing market price of common stock
Closing Market Price Of Common Stock
Aggregate intrinsic value of stock options exercised
Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value
Research and Development Expense
Research And Development Expense [Member]
General and Administrative Expense
General And Administrative Expense [Member]
Stock-based compensation expense
Operating Loss Carryforwards [Table]
Operating Loss Carryforwards [Table]
Income Tax Authority
Income Tax Authority [Axis]
Income Tax Authority
Income Tax Authority [Domain]
Federal
Domestic Country [Member]
Operating Loss Carryforwards [Line Items]
Operating Loss Carryforwards [Line Items]
Provision for income taxes
Income Tax Expense Benefit
Income tax reconciliation permanent items.
Income tax reconciliation change in fair value of warrants and convertible debt.
Income taxes computed at the statutory rate
Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate
Permanent items
Income Tax Reconciliation Permanent Items
Change in fair value of warrants and convertible debt
Income Tax Reconciliation Change In Fair Value Of Warrants And Convertible Debt
Research and development credit
Income Tax Reconciliation Tax Credits Research
Change in valuation allowance
Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance
Other
Income Tax Reconciliation Other Adjustments
Provision (benefit) for income taxes
Components Of Deferred Tax Assets [Abstract]
Deferred tax assets:
Deferred Tax Assets Net [Abstract]
Net operating loss carryforwards
Deferred Tax Assets Operating Loss Carryforwards
Research credits
Deferred Tax Assets Tax Credit Carryforwards Research
Intangible assets
Deferred Tax Assets Goodwill And Intangible Assets
Other
Deferred Tax Assets Other
Gross deferred tax assets
Deferred Tax Assets Gross
Less valuation allowance
Deferred Tax Assets Valuation Allowance
Deferred tax assets, net of valuation allowance
Deferred Tax Assets Net
Deferred tax liabilities:
Deferred Tax Liabilities Net [Abstract]
Other
Deferred Tax Liabilities Other
Net deferred tax assets
Deferred Tax Assets Liabilities Net
Operating loss carryforwards which are carried over indefinitely
Deferred Tax Assets Operating Loss Carryforwards Not Subject To Expiration
Research and development tax credit carry forward expiration year.
Research and development credits
Research and development credits expiration period
Research And Development Tax Credit Carry Forward Expiration Year
Beginning balance
Unrecognized Tax Benefits
Increases related to current year tax positions
Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions
Ending balance
Gross unrecognized tax benefits
Unrecognized tax benefits that would affect effective tax rate
Unrecognized Tax Benefits That Would Impact Effective Tax Rate
Interest or penalties related income tax
Unrecognized Tax Benefits Income Tax Penalties And Interest Expense
Accrual for interest or penalties related to income tax
Unrecognized Tax Benefits Income Tax Penalties And Interest Accrued
Defined contribution plan liabilities.
Defined contribution pan employer discretionary match number of shares settled.
Defined Contribution Plan [Table]
Defined Contribution Plan [Table]
Defined Contribution Plan Disclosure [Line Items]
Defined Contribution Plan Disclosure [Line Items]
Defined contribution plan employer contribution expense
Defined Contribution Plan Cost Recognized
Defined contribution plan liability
Defined Contribution Plans Liabilities
Defined contribution plan, employer matching contribution, percentage
Defined Contribution Plan Employer Matching Contribution Percent Of Match
Employer discretionary match number of shares settled
Defined Contribution Plan Employer Discretionary Match Number Of Shares Settled
Research and development
General and administrative
Total other income (expense)
Subsequent Event [Table]
Subsequent Event [Table]
Subsequent Event [Line Items]
Subsequent Event [Line Items]